Myasthenia gravis (MG) is an antibody-mediated, neuromuscular transmission disorder, which ranges in clinical manifestations of ocular myasthenia that may be visually disabling to myasthenic crisis with patients suffering life-threatening respiratory insufficiency. MG also has pathophysiologic subgroups based ...
Treatment of myasthenia gravis ; a comparison of the natural course and current therapies M Seto - 《Tohoku Journal of Experimental Medicine》 被引量: 0发表: 1993年 treatment of myasthenia gravis : a comparison of the natural course and current therapies M Seto,M Motomura,G Takeo,... 被引...
This article presents a summary of the new medications approved for generalized myasthenia gravis (gMG) since 2017. Pivotal clinical trials that led to the
Immunoactive treatment for myasthenia gravis; a Chinese experiencedoi:10.1111/cns.13466Nils Erik GilhusDepartment of Clinical Medicine University of Bergen Bergen Norway Department of Neurology Haukeland University Hospital Bergen NorwayJohn Wiley & Sons, LtdCNS Neuroscience & Therapeutics...
Myasthenia gravis(MG) is not an untreatable disease.Majority of patients will get satisfactory improvement even complete remission upon suitable managements.The review introduces the major methods treating MG,including anti-cholinesterase agents,corticosteroids therapy,chemotherapy,plasma-exchange,lymphocyte excha...
Treatment of Myasthenia Gravis Based on Its Immunopathogenesis The prognosis of myasthenia gravis (MG) has improved dramatically due to advances in critical-care medicine and symptomatic treatments. Its immunopathogene... KJ Young,PK Duk,DP Richman - 《Journal of Clinical Neurology》 被引量: 116发...
To describe the clinical presentation, diagnosis, and treatment of myasthenia gravis (MG) while emphasizing the important role of the pharmacist. English-language articles from MEDLINE pertinent to MG study selection and data extraction: All relevant publications addressing MG management were considered, ...
Substantial therapeutic progress has been made in myasthenia gravis (MG) even before the era of molecular medicine. Here we characterize modern treatment algorithms that are adapted to disease severity and introduce the principle of escalating treatment strategies for MG. In very mild cases and in so...
Opinion statementMyasthenia gravis (MG) is an autoimmune disorder that is characterized by variable weakness and fatigability. Often, MG presents with only ocular symptoms such as ptosis and diplopia. Treatment of ocular MG is aimed at relieving the symptoms of ptosis and diplopia, as well as pre...
(HealthDay)—Vyvgart (efgartigimod), a neonatal Fc receptor blocker (FcRn), was approved to treat generalized myasthenia gravis in adults who test positive for the anti-acetylcholine receptor (AChR) antibody, the U.S. Food and Drug Administration announc